$1.36 Billion is the total value of Consonance Capital Management LP's 24 reported holdings in Q4 2018. The portfolio turnover from Q3 2018 to Q4 2018 was 15.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| EXEL | Buy | EXELIXIS INC | $130,709,000 | +90.2% | 6,645,113 | +71.3% | 9.61% | +159.7% |
| AMRN | Buy | AMARIN CORP PLCspons adr new | $128,625,000 | +59.1% | 9,450,763 | +90.2% | 9.46% | +117.3% |
| VNDA | Buy | VANDA PHARMACEUTICALS INC | $121,733,000 | +19.4% | 4,658,759 | +4.8% | 8.95% | +63.0% |
| UTHR | Buy | UNITED THERAPEUTICS CORP DEL | $119,855,000 | +8.7% | 1,100,597 | +27.6% | 8.82% | +48.5% |
| RTRX | Buy | RETROPHIN INC | $91,247,000 | -18.9% | 4,032,123 | +3.0% | 6.71% | +10.8% |
| CORT | Buy | CORCEPT THERAPEUTICS INC | $82,992,000 | +17.5% | 6,211,964 | +23.3% | 6.10% | +60.5% |
| VCEL | Buy | VERICEL CORP | $73,395,000 | +24.4% | 4,218,092 | +1.2% | 5.40% | +70.0% |
| MYGN | Buy | MYRIAD GENETICS INC | $68,905,000 | -9.0% | 2,370,296 | +44.0% | 5.07% | +24.3% |
| LMNX | Buy | LUMINEX CORP DEL | $55,528,000 | -22.7% | 2,402,787 | +1.4% | 4.08% | +5.6% |
| QURE | Buy | UNIQURE NV | $54,649,000 | +43.7% | 1,896,226 | +81.4% | 4.02% | +96.2% |
| OXFD | Buy | OXFORD IMMUNOTEC GLOBAL PLC | $32,970,000 | -17.1% | 2,579,784 | +5.3% | 2.42% | +13.3% |
| CPRX | Buy | CATALYST PHARMACEUTICALS INC | $18,052,000 | -21.0% | 9,402,317 | +55.5% | 1.33% | +8.0% |
| ADMA | Buy | ADMA BIOLOGICS INC | $10,966,000 | -61.1% | 4,588,352 | +1.1% | 0.81% | -46.8% |
| New | RADIUS HEALTH INCnote 3.000% 9/0 | $6,900,000 | – | 9,000,000 | +100.0% | 0.51% | – | |
| AUPH | New | AURINIA PHARMACEUTICALS INC | $68,000 | – | 10,000 | +100.0% | 0.01% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| UNITED THERAPEUTICS CORP DEL | 29 | Q2 2022 | 15.9% |
| ADMA BIOLOGICS INC | 27 | Q4 2020 | 2.3% |
| RETROPHIN INC | 23 | Q1 2020 | 11.3% |
| ANI PHARMACEUTICALS INC | 23 | Q3 2019 | 7.9% |
| VERICEL CORP | 21 | Q4 2019 | 5.5% |
| AMARIN CORP PLC | 14 | Q3 2019 | 14.4% |
| GLOBUS MED INC | 13 | Q2 2022 | 24.7% |
| ORTHOFIX INTL N V | 13 | Q3 2016 | 9.7% |
| PACIFIC BIOSCIENCES CALIF IN | 13 | Q4 2018 | 9.7% |
| CATALYST PHARM PARTNERS INC | 13 | Q3 2019 | 9.4% |
View Consonance Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Surrozen, Inc./DESold out | December 15, 2022 | 0 | 0.0% |
| ADMA BIOLOGICS, INC. | February 14, 2022 | 1,289,481 | 1.4% |
| ASSEMBLY BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| CASI Pharmaceuticals, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Cellectar Biosciences, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Gamida Cell Ltd.Sold out | February 14, 2022 | 0 | 0.0% |
| GenMark Diagnostics, Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Protagonist Therapeutics, IncSold out | February 14, 2022 | 0 | 0.0% |
| Sio Gene Therapies Inc.Sold out | February 14, 2022 | 0 | 0.0% |
| Consonance-HFW Acquisition Corp. | April 27, 2021 | 1,000,000 | 10.4% |
View Consonance Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-12-15 |
| SC 13D/A | 2022-12-15 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
| SC 13G/A | 2022-02-14 |
View Consonance Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.